What You Need Reconstituted retatrutide vial or pen device Appropriate insulin syringe if drawing from a vial (see the retatrutide reconstitution guide for mixing steps) Alcohol swabs Sharps disposal container Optional: gauze or cotton ball for post-injection pressure Site Prep Steps Choose your site for this week from one of the 3 DailyMed-approved zones, rotating from last week's location Clean with an alcohol swab and allow the site to dry for 10 to 15 seconds before injecting (DailyMed label: "Clean the injection site with alcohol before injection") Pinch the skin gently if adequate subcutaneous fat is present, per MSKCC subcutaneous injection guidance Insert the needle at a 45 to 90 degree angle depending on needle length and tissue depth (shorter needles use 90 degrees
After you eat, your gut releases GLP-1 to send a simple message to your brain: "Hey, we're good here
Lisco and colleagues published a review of the risks of GLP-1s and thyroid cancer in the journal Endocrine Connections in 2023, and although they describe evidence for a risk of thyroid cancer, they conclude: It is reasonable to continue prescribing GLP-1RAs due to the evidence of more relevant and well-recognized antihyperglycemic, cardiovascular, and renal benefits, with the management staying within current recommendations. If you are considering taking a GLP-1 but are concerned about the risk of thyroid cancer, you should discuss it with your doctor
an -methyl-leucine alters conformation
| Center for Science in the Public Interest (CSPI)
In the primary Phase 2 clinical trial published in the New England Journal of Medicine (Jastreboff et al., 2023), retatrutide was studied across several dose levels, including: 1 mg (low dose) 4 mg (mid dose) 8 mg (higher dose) 12 mg (highest dose) These doses were administered as once-weekly subcutaneous injections